# US 2026/0062426 A1 · Cyclin dependent kinase degraders and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062426 A1
- Document ID: US20260062426A1
- Status: Published application
- Kind: A1
- Application number: 19/311,326
- Filed: 2025-08-27
- Published: 2026-03-05
- Earliest claimed: 2023-02-28
- Assignees: Differentiated Therapeutics Inc
- Applicants: Differentiated Therapeutics Inc
- Inventors: Timothy A. DWIGHT; Bryce K. ALLEN
- Web page: https://patentgrep.com/patent/US20260062426A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for degrading CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure.

## Claims

### Claim 1

A compound of Formula A-I:
or a pharmaceutically acceptable salt thereof, wherein:
s a single or a double bond;
Ring A is selected from the group consisting of a nitrogen-containing 4-10 member heterocyclyl, a C6-10 aryl and a 5-10-member heteroaryl, wherein the 4-10 member heterocyclyl, C6-10 aryl and 5-10-member heteroaryl are attached to the —NH— through a carbon atom;
V1 is nitrogen and V2 is carbon, and Ring
or V2 is nitrogen and V1 is carbon, and Ring
T is CH or N;
Q1 and Q2 are independently selected from N and CH;
R1A is independently selected from H, D, halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, 5-10 membered heteroaryl-C1-4 alkyl-, ORa1, SRa1 NHORa1, C(O)Rb1, C(O)NRa1Ra1, C(O)NRa1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRa1Ra1, NRa1Ra1, NRa1NRa1Ra1, NRa1C(O)Rb1, NRa1C(O)ORa1, NRa1C(O)NRa1Ra1, C(═NRa1)Rb1, C(═NRa1)NRa1Ra1, NRa1C(═NRa1)NRa1Ra1, NRa1C(═NRa1)Rb1, NRa1S(O)NRa1Ra1, NRa1S(O)Rb1, NRa1S(O)2Rb1, NRa1S(O)(═NRa1)Rb1, NRa1S(O)2NRa1Ra1, S(O)Rb1, S(O)NRa1Ra1, S(O)2Rb1, S(O)2NRa1Ra1, OS(O)(═NRa1)Rb1, OS(O)2Rb1, S(O)(═NRa1)Rb1, SF5, P(O)Ra1Rb1, OP(O)(ORa1)(ORa1) and P(O)(ORa1)(ORa1), wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl-, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, and 5-10 membered heteroaryl-C1-4 alkyl-are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents;
each R2 is independently selected from H, D, halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-7 cycloalkyl, phenyl, 4-7 membered heterocyclyl, 5-6 membered heteroaryl, C3-7 cycloalkyl-C1-4 alkyl-, phenyl-C1-4 alkyl-, 4-7 membered heterocyclyl-C1-4 alkyl-, 5-6 membered heteroaryl-C1-4 alkyl-, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRa2Ra2, C(O)NRa2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRa2Ra2, NRa2Ra2, NRa2NRa2Ra2, NRa2C(O)Rb2, NRa2C(O)ORa2, NRa2C(O)NRa2Ra2, C(═NRa2)Rb2, C(═NRa2)NRa2Ra2, NRa2C(═NRa2)NRa2Ra2, NRa2C(═NRa2)Rb2, NRa2S(O)NRa2Ra2, NRa2S(O)Rb2, NRa2S(O)2Rb2, NRa2S(O)(═NRa2)Rb2, NRa2S(O)2NRa2Ra2, S(O)Rb2, S(O)NRa2Ra2, S(O)2Rb2, S(O)2NRa2Ra2, OS(O)(═NRa2)Rb2, OS(O)2Rb2, S(O)(═NRa2)Rb2, SF5, P(O)Ra2Ra2, OP(O)(ORa2)(ORa2) and P(O)(ORa2)(ORa2), wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-7 cycloalkyl, phenyl, 4-7 membered heterocyclyl, 5-6 membered heteroaryl, C3-7 cycloalkyl-C1-4 alkyl-, phenyl-C1-4 alkyl, 4-7 membered heterocyclyl-C1-4 alkyl-, and 5-6 membered heteroaryl-C1-4 alkyl-are each substituted with 0, 1, 2, 3, or 4 substituents independently selected from C1-4 alkyl, C3-7 cycloalkyl, cyclopropyl, oxo, —C(O)C1-4alkyl, —C(O)OC1-4alkyl, —C(O)NH2, —OH, —F, —Cl, —O—C1-4alkyl and —CN;
each instance of RA is independently selected from —D, halo, CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocyclyl, ORa1, SRa1, SF5, NRa1Ra1, C3-6 cycloalkyl-C1-3 alkyl-, and 4-6 membered heterocyclyl-C1-3 alkyl-, wherein said C1-4 alkyl, C1-4haloalkyl-, C3-6 cycloalkyl, 4-6 membered heterocyclyl-, C3-6 cycloalkyl-C1-3 alkyl-, and 4-6 membered heterocyclyl-C1-3 alkyl are substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
or, alternatively, two RA groups on adjacent atoms of Ring A, together with the ring atoms to which they are attached, form Ring D, wherein Ring D is selected from C3-6 cycloalkyl, 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
each Ra1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl-, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, and 5-10 membered heteroaryl-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl, 6-10 membered aryl-C1-4 alkyl, 4-10 membered heterocyclyl-C1-4 alkyl, and 5-10 membered heteroaryl-C1-4 alkyl are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents; or two Ra1 groups attached to the same nitrogen atom together with the nitrogen to which they are attached form a 4-7-membered heterocyclyl group substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
each Rb1 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
each Ra2 is independently selected from H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl, or, when possible, two instances of Ra2 and the atom to which they are attached are taken together to form a 4-7 member heterocycle substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
each Rb2 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
X is X1 when Ring A is heterocyclyl and is selected from X1 and X2 when Ring A is aryl or heteroaryl;
X1 is selected from —S(O)2— and —C(O)—;
X2 is selected from —O—, —NH—, —N(CH3)— and —CH2—;
L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by —Cy—, —CH(R)—, —C(R)2—, —O—, —NR—, —S—, —OC(═O)—, —C(═O)O—, —C(═O)—, —S(═O)—, —S(═O)2—, —NRS(═O)2—, —S(═O)2NR—, —NRC(═O)—, —C(═O)NR—, —OC(═O)NR— or —NRC(═O)O—, wherein:
each —Cy— is independently a bivalent ring selected from phenylene, an 8-10 membered bicyclic arylene, a 4-7 membered monocyclic carbocyclylene, a 5-11 membered Spiro carbocyclylene, a 4-10 membered bicyclic carbocyclylene, a 5-10 membered bridged carbocyclylene, a 4-7 membered monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-11 membered spiro heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 4-10 membered bicyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bridged bicyclic saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylene having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each phenylene, arylene, carbocyclylene, heterocyclylene and heteroarylene is substituted with 0, 1, 2, 3, or 4 instances of RC;
LBM is selected from:
Ya is CH or N;
Za is a bond, —CH2—, —NH—, O, or —NHC(O)— where NH of —NHC(O)— is attached to Ya;
Ring B is phenylene, a 4-10-membered heterocyclylene, a 5-6-membered monocyclic heteroarylene or a 9-10-membered fused bicyclic heteroarylene, wherein each heteroarylene contains one to three nitrogen ring atoms.
ring C together with the (R4)r substituents is selected from the group consisting of:
each instance of Re is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R4 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R5 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R is independently selected from hydrogen and —C1-6 alkyl;
n is 0, 1, 2, 3, or 4;
r is 0, 1, 2, 3, or 4; and
s is 0, 1, 2, 3, or 4.

### Claim 2

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is selected from
each W1, W2, W3 and W4 is independently selected from CH and N, provided that no more than 2 of W1, W2, W3 and W4 are N;
T is CH or N;
R1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl, C3-10 cycloalkyl-C1-4 alkyl- and 4-10 membered heterocyclyl-C1-4 alkyl-, wherein said C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl, C3-10 cycloalkyl-C1-4 alkyl- and 4-10 membered heterocyclyl-C1-4 alkyl-, are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents;
each R2 is independently selected from D, halo, CN, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, ORa2, C(O)Rb2, C(O)NRa2Ra2, C(O)ORa2, OC(O)Rb2, OC(O)NRa2Ra2, NRa2Ra2, NRa2C(O)Rb2, NRa2C(O)ORa2, NRa2C(O)NRa2Ra2, NRa2S(O)NRa2Ra2, NRa2S(O)Rb2, NRa2S(O)2Rb2, NRa2S(O)2NRa2Ra2, S(O)Rb2, S(O)NRa2Ra2, S(O)2Rb2, S(O)2NRa2Ra2, SF5, wherein said C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl and 4-7 membered heterocyclyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-4 alkyl, C3-7 cycloalkyl, cyclopropyl, oxo, —C(O)C1-4alkyl, —C(O)OC1-4alkyl, —C(O)NH2, —OH, —F, —Cl, —O—C1-4alkyl and —CN;
each Ra2 is independently selected from H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl, or, when possible, two instances of Ra2 and the atom to which they are attached are taken together to form a saturated 3-7-membered heterocycle;
each Rb2 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by —Cy—, —CH(R)—, —C(R)2—, —O—, —NR—, —S—, —OC(═O)—, —C(═O)O—, —C(═O)—, —S(═O)—, —S(═O)2—, —NRS(═O)2—, —S(═O)2NR—, —NRC(═O)—, —C(═O)NR—, —OC(═O)NR— or —NRC(═O)O—, wherein:
each —Cy— is independently a bivalent ring selected from phenylene, an 8-10 membered bicyclic arylene, a 4-7 membered monocyclic carbocyclylene, a 5-11 membered spiro carbocyclylene, a 4-10 membered bicyclic carbocyclylene, a 5-10 membered bridged carbocyclylene, a 4-7 membered monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-11 membered spiro heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 4-10 membered bicyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bridged bicyclic saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylene having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each phenylene, arylene, carbocyclylene, heterocyclylene and heteroarylene is substituted with 0, 1, 2, 3, or 4 instances of RC;
LBM is selected from
each instance of RA is independently selected from —D, halogen, —C1-6 alkyl, —OH and —OC1-4 alkyl, wherein each —C1-6 alkyl is substituted with 0, 1, 2 or 3 groups independently selected from —D, —F, —OH and —OC1-4 alkyl or two RA groups on adjacent atoms of Ring A, together with the ring atoms to which they are attached, form Ring D, wherein Ring D is selected from C3-6 cycloalkyl, 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
each instance of RC is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R4 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R5 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
each instance of R is independently selected from hydrogen and —C1-6 alkyl;
n is 0, 1, 2, 3, or 4;
r is 0, 1, 2, 3, or 4; and
s is 0, 1, 2, 3, or 4.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula II-1

### Claim 6 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula III-1

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from C1-6 alkyl, C1-6 haloalkyl and C3-6 cycloalkyl, wherein said C1-6 alkyl, C1-6 haloalkyl and C3-6 cycloalkyl are each substituted with 0, 1 or 2 independently selected R2 substituents.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each RA is independently selected from —D, halogen, —C1-6 alkyl, —OH OCF3, —OCHF2, and —OC1-4 alkyl, wherein each —C1-6 alkyl is substituted with 0, 1, 2 or 3 groups independently selected from —D, —F, —OH and —OC1-4 alkyl or two RA are taken together with the atoms to which they are attached to form an aryl or heteroaryl.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0, 1 or 2.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the moiety represented by
is selected from NN IF
wherein the left attachment point connects to the —X— group of Formula A-I or the —S(O)2— group of formula I and the right attachment point connects to the —NH— group of Formula A-I and formula I.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV.

### Claim 39 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-a.

### Claim 40 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-b.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-e

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula IV-i:

### Claim 48 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is selected from
each substituted with 0, 1, 2 or 3 instances of R7, wherein each R7 is independently selected from —C1-4 alkyl and halo;
wherein the left attachment point connects to LBM and the right attachment point connects to the —X— group of Formula A-I or —S(O)2— group of Formula I and wherein
L1 and L2 are each independently selected from a bond and —N(R′), wherein R′ is selected from H and C1-6 alkyl; and
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently selected from —D, —Me, —Et, —F, —Cl and —OH.

### Claim 53

(canceled)

### Claim 54 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R5 is independently selected from —Me, —Et, —F, —Cl and —OH.

### Claim 55

(canceled)

### Claim 56 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein r is 0, 1 or 2, and wherein s is 0, 1 or 2.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein LBM is selected from:

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

### Claim 68

(canceled)

### Claim 69 (depends on 1)

A method of inhibiting CDK2 and/or CCNE (CCNE1 and/or CCNE2) signaling in a sample, e.g., in vivo or in vitro, by contacting CDK2 and/or CCNE (CCNE1 and/or CCNE2) with a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79

(canceled)

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84

(canceled)

### Claim 85

(canceled)

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90

(canceled)
